Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

Local Recurrence of Malignant Tumor of Prostate Clinical Trial

— STEREO-RE-PRO  

Official title:

Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03438552
• Other study ID #: GETUG-AFU 31 - UC-0160/1618
• Secondary ID: 2017-A00008-45
• Status: Recruiting
• Phase: N/A
• Start date: October 18, 2018
• Est. completion date: November 2030

Study information

• Verified date: November 2023
• Source: UNICANCER
• Contact: Soazig NENAN
• Phone: +33 (0)185 343 113
• Email: s-nenan[@]unicancer.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a supplementary non-invasive curative treatment for local recurrence following radiotherapy. The objective of the first part of the trial (Phase I) is to select the recommended dose for salvage SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT. Particular attention will be paid to the quality of life and tolerance of the treatment. The objective of the second part of the trial (phase II) is to estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate.

Description:

To date, no standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. A number of treatments options exist including: radical prostatectomy, brachytherapy, High-intensity focused ultrasound (HIFU), cryotherapy, and stereotactic radiotherapy. These treatments are associated with a variety of genitourinary and gastrointestinal toxicities and complications. In recent years, stereotactic radiotherapy has been used to treat localized prostate cancer in the primary setting but also as a salvage treatment after failure of radiotherapy. The initial results of these studies are promising, with respect to survival and tolerance, but further studies are required to confirm these initial results. The objective of STEREO-RE-PRO is to prospectively evaluate salvage SBRT for intraprostatic recurrent prostate cancer after primary external radiotherapy. This study will select patients for whom there is no standard local treatment. After inclusion and non-inclusion criteria have been verified and the patient has consented, the site will register the screening and organize the baseline visit with the placement of fiducial markers within two months before the planned start of SBRT. Once the fiducial placement has been performed and all eligibility criteria fully reviewed, the site will register the patient's participation so that the bio-statistician allocates the dose of SBRT. The dose will be allocated upon a model-based estimates provided by the statistical team and confirmed by the trial steering committee. Five or six fractions, at a level of 5 or 6 Gy per session (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), will be delivered over a maximum of 12 days to provide a total dose of 25 to 36 Gy. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care. A follow-up visit is planned at 6, 10, 18 weeks from the start of SBRT for safety evaluation. Subsequent follow-up visits are planned at 6, 9, 12, 18, 24, 30, and 36 months after the start of radiotherapy. Thereafter, yearly follow-up visits at 48, 60, and 72 months after starting SBRT will be planned after the initial 3-year follow-up period. M72 visit corresponds to the end of study visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 47
• Est. completion date: November 2030
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Biochemical recurrence occurring at least 2 years after external radiotherapy for prostatic adenocarcinoma by the Phoenix definition (PSA nadir + 2 ng/mL)
• T1-T2c and PSA =20 ng/mL and Gleason score =7 at initial diagnosis of prostate cancer before the initial/first treatment.
• Recurrence of prostatic adenocarcinoma proven by histology following radiotherapy by transrectal or transperineal sextant biopsies of the two lobes of the prostate, with a minimum of 12 biopsies, irrespective of Gleason score. Biopsies of the seminal vesicles are optional.
• Clinical stage T1-T2 on relapse; unilateral extracapsular extension (T3a) on MRI permitted except posteriorly relative to the rectum
• Estimated clinical target volume (CTV) / prostate volume < 0.5 based on imaging and biopsies
• Pelvic and prostatic assessment by multiparametric MRI- Absence of pelvic or metastatic recurrence proven by choline PET scan
• Performance status World Health Organization (WHO) 0-1
• PSA level =10 ng/mL at baseline (before salvage-SBRT)
• PSA doubling time >10 months
• International Prostate Cancer Score (IPSS) =12
• Uroflowmetry with a maximum flow rate >10 mL/s, a postvoid residual urine volume <150 mL, and a urine volume >150 mL.
• No other anti-cancer treatment since the external radiotherapy administered as first-line treatment
• No other anti-cancer treatment planned for the current recurrence
• No contraindication to fiducial marker implants; haemostatic disorders must be corrected before implantation
• Age >18 years
• Life-expectancy greater than or equal to 5 years (Lee scale)
• Patient registered with a health insurance system
• Patient who has signed the informed consent form
• Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

Exclusion Criteria:

• Lymph node or metastatic spread
• Late post-radiotherapy urinary or gastrointestinal toxicity of grade =2 (following primary radiotherapy)
• Other cancers in the last 5 years except for non-melanoma-type skin cancer
• History of inflammatory bowel disease
• Anticoagulant treatment
• Contraindications to undergoing MRI
• Prostate volume >80 cc
• Transurethral resection of the prostate (TURP) in the 6 months before registrations
• Presence of rectal telangiectasia grade 3 classified by the Vienna Rectoscopy Score (obligatory rectoscopy)
• Previous rectal surgery
• Patients unable to undergo medical follow-up in the study for geographical, social or psychological
• Person deprived of their liberty or under protective custody or guardianship
• Patients enrolled in another therapeutic study All patients during the SBRT planning with a ratio of clinical target volume (CTV) / prostate volume >0.5 will be withdrawn from the study. These patients will be considered as not evaluable and will not be treated within the context of the study.

Related Conditions & MeSH terms

• Local Recurrence of Malignant Tumor of Prostate
• Prostatic Neoplasms
• Recurrence

Intervention

Radiation:
• Stereotactic Body Radiotherapy
This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.

Locations

Country	Name	City	State
France	Centre François Baclesse	Caen
France	Centre Jean Perrin	Clermont-Ferrand
France	Centre George François Leclerc	Dijon
France	Centre Oscar Lambret	Lille
France	Centre Léon Bérard	Lyon
France	Institut régional du Cancer de Montpellier	Montpellier
France	Groupe Hospitalier Pitié-Salpétrière	Paris
France	CHU de Poitiers	Poitiers
France	DE CREVOISIER Renaud	Rennes
France	ICO -Site René Gauducheau	Saint-Herblain
France	Institut de Cancérologie Lucien Neuwirth	Saint-Priest-en-Jarez
France	CHRU Henry S.Kaplan	Tours
France	Institut de Cancérologie de Lorraine	Vandoeuvre-les-nancy

Sponsors (1)

Lead Sponsor	Collaborator
UNICANCER

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT.	The dose-escalation part of the study will terminate once 10 patients have been treated and evaluated at a dose currently identified as the recommended dose.	18 weeks
Primary	Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate		6 years
Secondary	Evaluation of acute and late genitourinary toxicities of the salvage-SBRT	Acute and late genitourinary toxicities over the first 3 years according to the NCI-CTCAE V4.03 classification (June 14th, 2010)	3 years
Secondary	Estimate the efficacy of the salvage-SBRT in terms of clinical progression-free survival and overall survival	Clinical progression-free survival is defined as the time interval between the date of registration and the date of clinical progression (local progression assessed by the physical examination, or appearance of metastatic lesions) or death irrespective of the cause.	6 years
Secondary	Evaluation of Quality of life after salvage-SBRT	Quality of life will be evaluated based on the EORTC QLQ-C30. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.	6 years
Secondary	Evaluation of Quality of life after salvage-SBRT	Quality of life will be evaluated based on the EORTC QLQ-PR25. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.	6 years